HPV L1 蛋白

人乳头瘤病毒(HPV)在全世界引起约5%的癌症病例。

持续感染高风险HPV(HR-HPV),包括 HPV(16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 70, 73, 82)可引起约94%的肛门癌,约63%的阴茎癌,约74%的阴道癌,约5-20%的头颈部鳞状细胞癌以及几乎所有的宫颈癌。

有一些预防性疫苗已被批准用于预防某些类型的HPV感染。疫苗由HPV的主要衣壳蛋白(L1)组装的的病毒样颗粒(VLP)组成。

重组 HPV L1 蛋白

HPV L1 蛋白特性

高纯度:

>95% as determined by SDS-PAGE

表达宿主:

Baculovirus-Insect Cells

低内毒素:

< 20 EU per mL protein as determined by the LAL method.

HPV L1 抗体 & 基因

HPV L1 抗体

货号 产品描述 应用 特异性
68009-MM01 HPV16 L1 Antibody (Conformational Antibody), Mouse MAb ELISA, IHC-P, FCM, ICC/IF, IF, IP HPV16 capsid L1

HPV L1 基因

HPV L2 试剂

HPV L1 参考文献

• Zhai et al.A Novel Candidate MS2 Phage VLP Vaccine Displaying a tandem HPV L2 Peptide offers Similar Protection in Mice to Gardasil-9.Antiviral Res. 2017 November ; 147: 116–123
• A. Touzeè et al. Production of recombinant virus-like particles from human papillomavirus types 6 and 11, and study of serological reactivities between HPV 6, 11, 16 and 45 by ELISA: implications for papillomavirus prevention and detection. FEMS Microbiology Letters 160 (1998) 111-118
• Stanley M1.HPV vaccination in boys and men.Hum Vaccin Immunother. 2014;10(7):2109-11.
• Stanley MA1, Sterling JC.Host responses to infection with human papillomavirus.Curr Probl Dermatol. 2014;45:58-74.

病毒研究工具试剂